Compare Biogen Inc (BIIB) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Schlumberger NV — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Schlumberger NV trades at $47.72 (market cap $71.08B). The key difference: Schlumberger NV is far larger — about 2.5× Biogen Inc's market cap, and Schlumberger NV pays a 2.48% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | SLB | |
|---|---|---|
Market Cap | $28.34B | $71.08B |
Sector | Health | Energy |
52-Week High | $216.63 | $58.01 |
52-Week Low | $122.68 | $31.72 |
Enterprise Value | $30.62B | $79.30B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
SLB trades at $47.36, down 0.84% on the day, with a neutral technical signal. The company reported revenue of $35.71 billion in 2025, with a net income margin of 9.26% and a P/E ratio of 20.86. Recent news includes a major EPC contract win for the Baleine Phase 3 development and a strategic alliance with Liberty Energy for data center infrastructure, highlighting diversification efforts.
The outlook is supported by strong analyst consensus with a $63.00 price target and 84.85% buy ratings, but risks include oil price volatility and a recent dip in profit margins. Earnings have consistently beaten expectations, providing fundamental strength amid market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
